Phase II Study of Fruquintinib Combined With Sintilimab and TACE for Inoperable Primary Hepatocellular Carcinoma

NCT05971199 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

27

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Fruquintinib
DRUG: Sintilimab
DEVICE: Transcatheter arterial chemoembolization（TACE）

Sponsor

Zhejiang Cancer Hospital